Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.
Explore our pipelineCORE NEUROLOGY PIPELINE | |||||
Indication | Preclinical | Phase 1/2 | Pivotal | Partner | Anticipated Milestones* |
Chronic Neuropathic Pain (Nav 1.7) | Data presented at ASGCT 2023 | Q4 24: Nav 1.7 IND submission | |||
Prion Disease | Data presented at Prion 2023 | Q4 25: Prion CTA submission | |||
Tauopathies | As early as Q4 25: Tau IND submission | ||||
ALS/FTD | |||||
Huntington's Disease |
OTHER PROGRAMS | |||||
Indication | Preclinical | Phase 1/2 | Pivotal | Partner | Anticipated Milestones* |
Hemophilia A (Giroctogene fitelparvovec) | Data presented at ASH 2023 |
Mid-2024: Phase 3 AFFINE trial pivotal readout
Early 2025: BLA and MAA submissions |
|||
Fabry Disease (Isaralgagene civaparvovec) | Data presented at WORLDSymposium 2024 | IH24: Phase 1/2 STAAR study dosing completion | |||
Renal Transplant (TX200) | Six patients dosed in Phase 1/2 | IH24: Phase 1/2 STEADFAST study dosing completion |